NZ534479A - Combination preparation of the sodium-hydrogen exchange inhibitor cariporide with ACE inhibitors for preventing heart failure and other age-related dysfunctions of organs, age-related diseases and for prolonging lifespan - Google Patents

Combination preparation of the sodium-hydrogen exchange inhibitor cariporide with ACE inhibitors for preventing heart failure and other age-related dysfunctions of organs, age-related diseases and for prolonging lifespan

Info

Publication number
NZ534479A
NZ534479A NZ534479A NZ53447903A NZ534479A NZ 534479 A NZ534479 A NZ 534479A NZ 534479 A NZ534479 A NZ 534479A NZ 53447903 A NZ53447903 A NZ 53447903A NZ 534479 A NZ534479 A NZ 534479A
Authority
NZ
New Zealand
Prior art keywords
age
organs
sodium
heart failure
ace inhibitors
Prior art date
Application number
NZ534479A
Inventor
Wolfgang Linz
Ursula Schindler
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NZ534479A publication Critical patent/NZ534479A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Disclosed is a cariporide (sodium-hydrogen exchanger) and ramipril (angiotensin converting enzyme inhibitor) combination product. The use of the preparation is disclosed to be for preventing or delaying age-related dysfunctions of organs, especially heart failure, and for prolonging lifespan.
NZ534479A 2002-02-04 2003-01-22 Combination preparation of the sodium-hydrogen exchange inhibitor cariporide with ACE inhibitors for preventing heart failure and other age-related dysfunctions of organs, age-related diseases and for prolonging lifespan NZ534479A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10204571 2002-02-04
PCT/EP2003/000587 WO2003066045A1 (en) 2002-02-04 2003-01-22 Combination preparation of the sodium-hydrogen exchange inhibitor cariporide with ace inhibitors for preventing heart failure and other age-related dysfunctions of organs, age-related diseases and for prolonging lifespan

Publications (1)

Publication Number Publication Date
NZ534479A true NZ534479A (en) 2006-03-31

Family

ID=27674558

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ534479A NZ534479A (en) 2002-02-04 2003-01-22 Combination preparation of the sodium-hydrogen exchange inhibitor cariporide with ACE inhibitors for preventing heart failure and other age-related dysfunctions of organs, age-related diseases and for prolonging lifespan

Country Status (23)

Country Link
EP (1) EP1474134B1 (en)
JP (1) JP4733348B2 (en)
KR (1) KR20040083498A (en)
CN (1) CN1319528C (en)
AR (1) AR038387A1 (en)
AT (1) ATE520398T1 (en)
AU (1) AU2003244430A1 (en)
BR (1) BR0307443A (en)
CA (1) CA2474888A1 (en)
CO (1) CO5601009A2 (en)
HR (1) HRP20040702A2 (en)
HU (1) HUP0402593A2 (en)
MA (1) MA27170A1 (en)
MX (1) MXPA04007569A (en)
NO (1) NO20043698L (en)
NZ (1) NZ534479A (en)
PE (1) PE20040188A1 (en)
PL (1) PL370488A1 (en)
RS (1) RS68204A (en)
RU (1) RU2004126702A (en)
TW (1) TW200306850A (en)
WO (1) WO2003066045A1 (en)
ZA (1) ZA200406066B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2795053A1 (en) * 2010-03-31 2011-10-06 The Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0855392A3 (en) * 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Five-membered heterocycles having biphenylsulphonyl substituents, processes for the preparation thereof, their use as medicaments or diagnostic agent and medicaments containing them
DE19734693A1 (en) * 1997-08-11 1998-01-22 Hoechst Marion Roussel De Gmbh Use of cariporide to treat cardiac and non-cardiac disease
DE19737224A1 (en) * 1997-08-27 1999-03-18 Hoechst Marion Roussel De Gmbh Pharmaceutical preparation for cardiovascular treatment
US6011059A (en) * 1997-12-24 2000-01-04 Bristol-Myers Squibb Company Acyl guanidine sodium/proton exchange inhibitors and method
DE19859727A1 (en) * 1998-12-23 2000-06-29 Aventis Pharma Gmbh The use of inhibitors of the sodium-hydrogen exchanger for the manufacture of a medicament for the prevention of age-related organ dysfunctions, age-related illnesses for the prolongation of life

Also Published As

Publication number Publication date
RS68204A (en) 2007-02-05
BR0307443A (en) 2005-01-04
WO2003066045A1 (en) 2003-08-14
PE20040188A1 (en) 2004-05-17
CA2474888A1 (en) 2003-08-14
ATE520398T1 (en) 2011-09-15
HUP0402593A2 (en) 2005-04-28
PL370488A1 (en) 2005-05-30
KR20040083498A (en) 2004-10-02
JP2005519072A (en) 2005-06-30
CO5601009A2 (en) 2006-01-31
ZA200406066B (en) 2005-06-08
CN1694697A (en) 2005-11-09
JP4733348B2 (en) 2011-07-27
EP1474134B1 (en) 2011-08-17
AR038387A1 (en) 2005-01-12
RU2004126702A (en) 2005-04-20
TW200306850A (en) 2003-12-01
MA27170A1 (en) 2005-01-03
NO20043698L (en) 2004-08-31
CN1319528C (en) 2007-06-06
EP1474134A1 (en) 2004-11-10
MXPA04007569A (en) 2004-11-01
AU2003244430A1 (en) 2003-09-02
HRP20040702A2 (en) 2005-04-30

Similar Documents

Publication Publication Date Title
SG148857A1 (en) N3 alkylated benzimidazole derivatives as mek inhibitors
WO2005049022A3 (en) Use of dipeptidyl peptidase iv inhibitors
WO2006087077A3 (en) Hsp90-inhibiting triazole derivatives
IL179607A0 (en) Indoles useful in the treatment of inflammation
ZA200501677B (en) Hydantoin derivatives and their use as TACE inhibitors.
TR199902923T2 (en) Yumu�ak kas h�cresi�o�almas� olarak (imidazole-5-yl)methyl-2-quinolinone trevleri inhibitor.
PL370478A1 (en) Aminoindazole derivatives as protein-kinase inhibitors
PL376129A1 (en) Pyridazinone derivatives as gsk-3beta inhibitors
GEP20063767B (en) Spiro-Hydantoin Compounds Useful as Anti-Inflammatory Agents
GEP20104974B (en) Carbonylamino pyrrolopyrazoles, protent kinase inhibitors
AU2003261434A1 (en) Iminothiazolidinones as inhibitors of hcv replication
AR039428A1 (en) PERINDOPRILE SALT AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AU2003261319A8 (en) Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
AU2003269628A1 (en) Non-nucleoside reverse transcriptase inhibitors
NO20052549L (en) Use of a PPARalpha agonist and metformin for reducing serum triglycerides.
NZ534479A (en) Combination preparation of the sodium-hydrogen exchange inhibitor cariporide with ACE inhibitors for preventing heart failure and other age-related dysfunctions of organs, age-related diseases and for prolonging lifespan
AU2003301903A8 (en) Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
AU2003217916A8 (en) Stable formulations of angiotensin converting enzyme (ace) inhibitors
AU2003242592A1 (en) Amide derivatives as inhibitors of the enzymatic activity of renin
ZA200104301B (en) The utilisation of inhibitors of the sodium hydrogen exchanger for producing a medicament for preventing organ dysfunctions and diseases relaed to a particular age and for prolonging life.
UA97249C2 (en) Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors for inhibiting the growth of tumor cells
AU2003290417A8 (en) Process for the preparation of angiotensin converting enzyme (ace) inhibitors and its use
WO2004037233A3 (en) Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
EP1500402A4 (en) Cell death inhibitor
EP1325918A4 (en) Heart muscular cell apoptosis inhibitors and remedies/preventives for heart diseases

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)